Introduction: Why Conventional Analytical Methods Are Insufficient for Nitrosamines For pharmaceutical manufacturers facing increasing regulatory scrutiny regarding genotoxic impurities, conventional […]
Introduction: Nitrosamine impurities are among the most scrutinized safety concerns in modern pharmaceutical development, and no NDA or BLA submission
Nitrosamine Risk Assessment and Testing Services for NDA and BLA Submissions Read More »
Introduction: Why a Single Nitrosamine Testing Panel Is Insufficient for Cardiac Drug Classes Understanding drug-class-specific nitrosamine chemistry is one of
Introduction: Pharmaceutical manufacturers function under rigorous oversight from major global regulatory agencies, including the United States Food and Drug Administration
Outsourcing Nitrosamine Testing to a CRO: Scope of Work, Timeline, and Cost Expectations Read More »
Introduction: The Expanding Regulatory Landscape for Nitrosamine Impurities in Biologics The nitrosamine crisis that affected the small-molecule pharmaceutical industry between
Introduction: Why Nitrosamines in Transdermal Patches and Topical Formulations Require Specialized Attention Over the past several years, the pharmaceutical and
Introduction: Nitrosamine Testing Inhalation Drug Products MDI DPI Nasal Spray has become a critical focus area for pharmaceutical manufacturers after
Nitrosamine Testing for Inhalation Drug Products: MDIs, DPIs, and Nasal Sprays Read More »
Introduction: Why Conventional Mutagenicity Models Are Inadequate for NDSRIs The regulatory complexity associated with N-Nitrosamine Drug Substance-Related Impurities (NDSRIs) extends
Introduction: Why Nitrosamines Require a Distinct Focus Within ICH M7 Genotoxic Impurity Testing When ICH M7 was finalized in 2014,
Genotoxic Impurity Testing: Where Nitrosamines Fit Within the Broader ICH M7 Framework Read More »
Introduction: When the Synthesis Route Itself Becomes the Problem The pharmaceutical industry’s encounter with nitrosamine contamination has revealed an important
